| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 889 | 892 | 865 | 602 |
| Research and development | 58,902 | 69,894 | 72,484 | 82,160 |
| Acquired in-process research and development | 0 | 96,253 | - | - |
| General and administrative | 16,931 | 18,916 | 19,296 | 17,419 |
| Collaboration expense, net | 57,115 | 45,153 | 57,509 | 11,153 |
| Total operating expenses | 132,948 | 230,216 | 149,289 | 110,732 |
| Loss from operations | -132,059 | -229,324 | -148,424 | -110,130 |
| Other income, net | 26,237 | 22,067 | 13,537 | 25,064 |
| Total other income, net | 26,237 | 22,067 | 13,537 | 25,064 |
| Net loss before income taxes | -105,822 | -207,257 | -134,887 | -85,066 |
| Provision for income taxes | 619 | 1,292 | 1,109 | 876 |
| Net loss | -106,441 | -208,549 | -135,996 | -85,942 |
| Foreign currency translation adjustment | -28 | 80 | 41 | 76 |
| Unrealized gain on marketable securities | 973 | -174 | 2,254 | 13,368 |
| Comprehensive loss | -105,496 | -208,643 | -133,701 | -72,498 |
| Basic net (loss) income per common share | -1.17 | -2.4 | -1.58 | -1.01 |
| Diluted net (loss) income per common share | -1.17 | -2.4 | -1.58 | -1.01 |
| Weighted average number of shares outstanding, basic, total | 91,305,337 | 87,069,690 | 85,938,720 | 85,234,926 |
| Weighted average number of shares outstanding, diluted | 91,305,337 | 87,069,690 | 85,938,720 | 85,234,926 |
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP)